Activated microglia and infiltrating lymphocytes are neuropathological hallmarks of amyotrophic lateral sclerosis (ALS), a fatal motoneuron disease. Although both cell types play pivotal roles in the ALS pathogenic process, the interactions between microglia and lymphocytes, specifically regulatory CD4 Tregs, were increased in ALS mice compared with WT mice; Tregs isolated during this phase reduced Teff proliferation. In contrast, during the rapidly progressing phase, the number of mSOD1 Tregs decreased while the proliferation of mSOD1 Teffs increased. The combination of IL-4, IL-10, and TGF-β was required to inhibit the proliferation of mSOD1 Teffs by mSOD1 Tregs that were isolated during the slow phase, while inhibition of mSOD1 Teffs by mSOD1 Tregs during the rapid phase, as well as WT Teffs, was not dependent on these factors. Thus, mSOD1 Tregs at the slow phase suppressed microglial toxicity and SOD1 Teff proliferation through different mechanisms; microglial activation was suppressed through IL-4 whereas mSOD1 Teffs were suppressed by IL-4, IL-10 and TGF-β. These data suggest that mSOD1 Tregs contribute to the slowly progressing phase in ALS mice and may offer a novel therapeutic option for ALS patients.
Activated microglia and infiltrating lymphocytes are neuropathological hallmarks of amyotrophic lateral sclerosis (ALS), a fatal motoneuron disease. Although both cell types play pivotal roles in the ALS pathogenic process, the interactions between microglia and lymphocytes, specifically regulatory CD4 Tregs, were increased in ALS mice compared with WT mice; Tregs isolated during this phase reduced Teff proliferation. In contrast, during the rapidly progressing phase, the number of mSOD1 Tregs decreased while the proliferation of mSOD1 Teffs increased. The combination of IL-4, IL-10, and TGF-β was required to inhibit the proliferation of mSOD1 Teffs by mSOD1 Tregs that were isolated during the slow phase, while inhibition of mSOD1 Teffs by mSOD1 Tregs during the rapid phase, as well as WT Teffs, was not dependent on these factors. Thus, mSOD1 Tregs at the slow phase suppressed microglial toxicity and SOD1 Teff proliferation through different mechanisms; microglial activation was suppressed through IL-4 whereas mSOD1 Teffs were suppressed by IL-4, IL-10 and TGF-β. These data suggest that mSOD1 Tregs contribute to the slowly progressing phase in ALS mice and may offer a novel therapeutic option for ALS patients. © 2012 Elsevier Inc. All rights reserved.
Amyotrophic lateral sclerosis (ALS), known as Lou Gehrig's disease, is the most common, devastating, and invariably fatal adult motoneuron disease. About 10% of ALS patients have a family history of the disease and approximately 20% of these patients have mutations in the Cu 2+ /Zn 2+ superoxide dismutase (SOD1) gene. Transgenic mice over-expressing several of these mutations (mSOD1) develop a disease replicating many of the clinical and pathological features of ALS (Appel et al., 2010; Henkel et al., 2009) . Of critical importance is the fact that mSOD1 mice show similar central nervous system (CNS) inflammatory changes that are present in ALS patients and that these changes coincide with disease onset, and parallel disease progression rates (Alexianu et al., 2001; Almer et al., 1999 Almer et al., , 2001 . Accumulating evidence suggests that through their distinctive temporal and spatial contributions, microglia and lymphocytes can have both neurotoxic and neuroprotective functions depending on their activation states and the physiologic conditions they encounter in the CNS (Appel et al., 2010; Schwartz and Kipnis, 2011) . Microglial activation is a major component of the neuroinflammatory response following CNS injury and numerous studies have confirmed the presence of activated microglia in regions of motoneuron damage in both ALS patients and mSOD1 mice (Alexianu et al., 2001; Hall et al., 1998; Turner et al., 2004) . On one hand, activated microglia exert their toxic effects on neurons through the release of substances such as free radicals (superoxide and nitric oxide) and neurotoxic pro-inflammatory cytokines (Alexianu et al., 2001; Bruijn et al., 2004; Henkel et al., 2004 Henkel et al., , 2006 Weydt et al., 2002) . We recently demonstrated that through these factors, and through the decrease of IGF-1, classically activated microglia were cytotoxic to motoneurons; in vitro studies utilizing primary microglia/motoneuron co-cultures provided evidence that mSOD1 microglia were more neurotoxic than wild-type (WT) microglia due to their enhanced release of free radicals and proinflammatory cytokines, and attenuated release of neurotrophic 
